Abstract
Cardiovascular diseases are among the most threatening problems being faced by twenty-first century humans. The core cause of these diseases is high cholesterol level. Simvastatin (1: Synvinolin) is a well-known cholesterol-lowering drug marketed under the trade name Zocor®, which significantly reduces the risk of cardiovascular diseases related to hypercholesterolemia and is effective in lowering the total plasma cholesterol, low-density and very low-density lipoprotein cholesterol. It also enhances the high-density lipoprotein cholesterol. This review article aims to provide an overview of several chemical and biological methods utilized for the production of simvastatin in high yields and purity. Many robust and scalable methods have been described using lovastatin (2: Mevinolin) as a starting material, produced by the fungal strain of Aspergelius terreus. Enzymatic synthesis of simvastatin is also highlighted in this review. In addition, detailed experimental conditions, as well as the compatibility for industrial-scale preparations of simvastatin are also discussed.
Keywords: Simvastatin, cholesterol, lovastatin, chemical synthesis, biocatalytic synthesis, cardiovascular diseases.
Graphical Abstract
[1]
(a) Schachter, M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam. Clin. Pharmacol., 2004, 19, 117-125.
(b) Florey, K. Analytical Profiles of Drug Substances; Academic Press: New York, 1973, Vol. 2, .
(c) Adler, S.; Huang, H.; Trochu, J.N.; Xu, X.; Gupta, S.; Hintze, T.H. Simvastatin reverses impaired regulation of renal oxygen consumption in congestive heart failure. Am. J. Physiol. Renal Physiol., 2001, 281(5), 802-809.
(b) Florey, K. Analytical Profiles of Drug Substances; Academic Press: New York, 1973, Vol. 2, .
(c) Adler, S.; Huang, H.; Trochu, J.N.; Xu, X.; Gupta, S.; Hintze, T.H. Simvastatin reverses impaired regulation of renal oxygen consumption in congestive heart failure. Am. J. Physiol. Renal Physiol., 2001, 281(5), 802-809.
[2]
(a) Saunders, K.D.; Cates, J.A.; Abedin, M.Z.; Roslyn, J.J. Lovastatin and gallstone dissolution: A preliminary study. Surgery, 1993, 113(1), 28-35.
(b) Gazzerro, P.; Proto, M.C.; Gangemi, G.; Malfitano, A.M.; Ciaglia, E.; Pisanti, S.; Santoro, A.; Laezza, C.; Bifulco, M.; Michael, M.G. Pharmacological actions of statins: A critical appraisal in the management of cancer. Pharmacol. Rev., 2012, 64(1), 102-146.
(c) Tazuma, S.; Hatsushika, S.; Aihara, N.; Sagawa, H.; Yamashita, G.; Sasaki, M.; Sasaki, H.; Mizuno, S.; Tao, S.; Kajiyama, G. Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs. Digestion, 1992, 51(3), 179-184.
(b) Gazzerro, P.; Proto, M.C.; Gangemi, G.; Malfitano, A.M.; Ciaglia, E.; Pisanti, S.; Santoro, A.; Laezza, C.; Bifulco, M.; Michael, M.G. Pharmacological actions of statins: A critical appraisal in the management of cancer. Pharmacol. Rev., 2012, 64(1), 102-146.
(c) Tazuma, S.; Hatsushika, S.; Aihara, N.; Sagawa, H.; Yamashita, G.; Sasaki, M.; Sasaki, H.; Mizuno, S.; Tao, S.; Kajiyama, G. Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs. Digestion, 1992, 51(3), 179-184.
[3]
(a) Grundy, S.M. Drugs for lipids. Treat. Guidel. Med. Lett., 2011, 9(103), 13-20.
(b) Weinreich, M.; Frishman, W.H. Antihyperlipidemic therapies targeting PCSK9. Cardiol. Rev., 2014, 22(3), 140-146.
(b) Weinreich, M.; Frishman, W.H. Antihyperlipidemic therapies targeting PCSK9. Cardiol. Rev., 2014, 22(3), 140-146.
[4]
(a) Smith, A. Zocor and Zoloft face patent expiration: Merck and Pfizer both
stand to lose billions of dollars in sales. Retrieved., 11, 2009.(available at. https://money.cnn.com/2006/06/15/news/companies/zoloft_zocor/index.htm
(b) Duane, W.C.; Hunninghake, D.B.; Freeman, M.L.; Pooler, P.A.; Schlasner, L.A.; Gebhard, R.L. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology, 1988, 8(5), 1147-1150.
(c) Anders, G. O.; Jorgen, M.; Henning, V. S. Synvinolin in hypercholesterolaemia., 1986, 328(8503), 390-391.
(b) Duane, W.C.; Hunninghake, D.B.; Freeman, M.L.; Pooler, P.A.; Schlasner, L.A.; Gebhard, R.L. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology, 1988, 8(5), 1147-1150.
(c) Anders, G. O.; Jorgen, M.; Henning, V. S. Synvinolin in hypercholesterolaemia., 1986, 328(8503), 390-391.
[5]
Endo, A. Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase. J. Antibiot. (Tokyo), 1980, 33(3), 334-336.
[6]
Hendrickson, L.; Davis, C.R.; Roach, C.; Nguyen, D.K.; Aldrich, T.; McAda, P.C.; Reeves, C.D. Lovastatin biosynthesis in Aspergillus terreus: Characterization of blocked mutants, enzyme activities and a multifunctional polyketide synthase gene. Chem. Biol., 1999, 6(7), 429-439.
[7]
Kennedy, J.; Auclair, K.; Kendrew, S.G.; Park, C.; Vederas, J.C.; Hutchinson, C.R. Modulation of polyketide synthase activity by accessory proteins during lovastatin biosynthesis. Science, 1999, 284(5418), 1368-1372.
[8]
(a) Tobert, J.A. Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov., 2003, 2(7), 517-526.
(b) Todd, P.A.; Goa, K.L. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs, 1990, 40(4), 583-607.
(b) Todd, P.A.; Goa, K.L. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs, 1990, 40(4), 583-607.
[9]
Sánchez-Quesada, J.L.; Otal-Entraigas, C.; Franco, M.; Jorba, O.; González-Sastre, F.; Blanco-Vaca, F.; Ordóñez-Llanos, J. Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol., 1999, 84(6), 655-659.
[10]
McKenney, J.; Ballantyne, C.M.; Feldman, T.A.; Brady, W.E.; Shah, A.; Davies, M.J.; Palmisano, J.; Mitchel, Y.B. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. MedGenMed, 2005, 7(3), 3.
[11]
Endo, A.; Kuroda, M.; Tsujita, Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J. Antibiot. (Tokyo), 1976, 29(12), 1346-1348.
[12]
(a) Kumar Basniwal, P.; Jain, D. Simvastatin: review of updates on recent trends in pharmacokinetics, pharmacodynamics, drug–drug interaction, impurities and analytical methods. Curr. Pharm. Anal., 2012, 8(2), 135-156.
(b) Nikolic, T.; Zivkovic, V.; Srejovic, I.; Stojic, I.; Jeremic, N.; Jeremic, J.; Radonjic, K.; Stankovic, S.; Obrenovic, R.; Djuric, D.; Jakovljevic, V. Effects of atorvastatin and simvastatin on oxidative stress in diet-induced hyperhomocysteinemia in Wistar albino rats: A comparative study. Mol. Cell. Biochem., 2018, 437(1-2), 109-118.
(b) Nikolic, T.; Zivkovic, V.; Srejovic, I.; Stojic, I.; Jeremic, N.; Jeremic, J.; Radonjic, K.; Stankovic, S.; Obrenovic, R.; Djuric, D.; Jakovljevic, V. Effects of atorvastatin and simvastatin on oxidative stress in diet-induced hyperhomocysteinemia in Wistar albino rats: A comparative study. Mol. Cell. Biochem., 2018, 437(1-2), 109-118.
[13]
(a) Gotto, A.M., Jr Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. Am. J. Cardiol., 2005, 96(5A), 34F-38F.
(b) Mauro, V.F.; MacDonald, J.L. Simvastatin: a review of its pharmacology and clinical use. DICP, 1991, 25(3), 257-264.
(b) Mauro, V.F.; MacDonald, J.L. Simvastatin: a review of its pharmacology and clinical use. DICP, 1991, 25(3), 257-264.
[14]
Ward, S.; Lloyd Jones, M.; Pandor, A.; Holmes, M.; Ara, R.; Ryan, A.; Yeo, W.; Payne, N. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol. Assess., 2007, 11(14), 1-160. [iii-iv.].
[15]
(a) Pedersen, T.R.; Tobert, J.A. Simvastatin: A review. Expert Opin. Pharmacother., 2004, 5(12), 2583-2596.
(b) Wagner, J. A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents: implications for dosing guidelines. Clin. Pharmacol. Ther., 2019, 75, 1227-1235.
(c) Golomb, B.A.; Evans, M.A. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am. J. Cardiovasc. Drugs, 2008, 8(6), 373-418.
(b) Wagner, J. A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents: implications for dosing guidelines. Clin. Pharmacol. Ther., 2019, 75, 1227-1235.
(c) Golomb, B.A.; Evans, M.A. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am. J. Cardiovasc. Drugs, 2008, 8(6), 373-418.
[16]
Kysilka, R.; Křen, V. Determination of Lovastatin (mevinolin) and mevinolinic acid in fermentation liquids. J. Chromatogr. A, 1993, 630(1-2), 415-417.
[17]
Hoffman, W.F.; Alberts, A.W.; Anderson, P.S.; Chen, J.S.; Smith, R.L.; Willard, A.K. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin. J. Med. Chem., 1986, 29(5), 849-852.
[18]
Hong, C.I.; Kim, J.W.; Shin, H.J.; Kang, T.W.; Cho, D.O. Process for
preparing simvastatin. US Patent 6,833,461., 2004.
[19]
Sleteinger, M.; Verhoeven, T.R.; Volante, R.P. Process for C-methylation of
2-methylbutyrates. US Patent 4,582,915., 1986.
[20]
Chatterjee, S.; Rawat, A.S.; Kumar, N.; Rajanikanth, J.; Shekhawat, K.S.; Shah, J.H.; Venkateswarlu, P. Process for preparing substantially pure
simvastatin. U.S. Patent Application No. 12/832,263., 2011.
[21]
Treiber, L.R. Process for the lactonization of mevinic acids and analogs
thereof. US Patent 4,916,239., 1990.
[22]
Hoffman, W.F.; Alberts, A.W.; Anderson, P.S.; Chen, J.S.; Smith, R.L.; Willard, A.K. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin. J. Med. Chem., 1986, 29(5), 849-852.
[23]
Verhoeven, T.R.; Askin, D. Process for α-C-alkylation of the 8-acyl group on
mevinolin and analogs thereof. US Patent 4,820,850., 1989.
[24]
Askin, D.; Verhoeven, T.; Liu, T.; Shinkai, I. Synthesis of synvinolin: Extremely high conversion alkylation of an ester enolate. J. Org. Chem., 1991, 56(16), 4929-4932.
[26]
Kubela, R.; Radhakrishnan, J. Process for producing simvastatin and analogs
thereof. US Patent US5,393,893., 1995.
[27]
Thaper, R.K.; Kumar, Y.; Dileep Kumar, S.; Misra, S.; Khanna, J.M. A cost-efficient synthesis of simvastatin via high-conversion methylation of an alkoxide ester enolate. Org. Process Res. Dev., 1999, 3(6), 476-479.
[28]
Murthy, K.K.; Horne, S.E.; Weeratunga, G.; Young, S. Process for producing
simvastatin. US Patent US6307066 B1., 2001.
[30]
Karimian, K.; Tam, T.F.; Tao, Y.; Li, Y.; Doucette, G. Process to
manufacture simvastatin and intermediates. US Patent US 6,506,929 B1.,
2003.
[31]
Dabak, K.; Adiyaman, M. A new method for the synthesis of antihypercholesterolemic agent simvastatin. Helv. Chim. Acta, 2003, 86(3), 673-677.
[32]
Lee, K-H.; Kim, J-W.; Choi, K-D.; Bae, H. Process for producing
simvastatin. Us Patent US 6,576,775 B1., 2003.
[33]
Sambasivam, G.; Sridharan, M.; Acharya, P.; Mathew, J. Process for
manufacturing Simvastatin and novel intermediates thereof. US Patent
US6603022B1., 2003.
[34]
Dabak, K.; Keskin, H. A convenient procedure for the methylation of lovastatin: synthesis of simvastatin. Heterocycl. Commun., 2004, 10(1), 29-34.
[35]
Khanna, J.M.; Kumar, Y.; Thaper, R.K.; Misra, S.; Kumar, S.D. Key
intermediates in the manufacture of simvastatin. US Patent US5763653A.,
1998.
[36]
Dandala, R.; Sebastian, S.; Reddy, S.J.M.; Sivakumaran, M. Process for
lactonization to produce simvastatin. US Patent US6797831B2., 2004.
[37]
Korodi, F. Process for preparing simvastatin and intermediates thereof. U.S.
Patent 2007/0129437 A1., 2007.
[38]
(a) Gudipati, S.; Mandava, V.N.B.; Setty, R.K.S.; Manne, N.; Sagyam, R.; Vujjini, S.K. Process for preparing simvastatin. U.S. Patent
US20070117996A1. 2007.
(b) Singamsetty, R.K.; Vujjini, S.K.; Manne, N.; Venkata Naga, B.R.M.; Himabindu, V.; Battacharya, A.; Ghanta, M.R.; Bandichhor, R. New synthesis of simvastatin. Synth. Commun., 2008, 38(24), 4452-4459.
(b) Singamsetty, R.K.; Vujjini, S.K.; Manne, N.; Venkata Naga, B.R.M.; Himabindu, V.; Battacharya, A.; Ghanta, M.R.; Bandichhor, R. New synthesis of simvastatin. Synth. Commun., 2008, 38(24), 4452-4459.
[39]
Shenqing, F.Z. Preparation of Simvastatin in ionic liquid. Chinese Patent
CNXXEV; CN104744416., 2015.
[40]
Xie, X.; Watanabe, K.; Wojcicki, W.A.; Wang, C.C.; Tang, Y. Biosynthesis of lovastatin analogs with a broadly specific acyltransferase. Chem. Biol., 2006, 13(11), 1161-1169.
[41]
(a) Gao, X.; Wang, P.; Tang, Y. Engineered polyketide biosynthesis and biocatalysis in Escherichia coli. Appl. Microbiol. Biotechnol., 2010, 88(6), 1233-1242.
(b) Xie, X.; Tang, Y. Efficient synthesis of simvastatin by use of whole-cell biocatalysis. Appl. Environ. Microbiol., 2007, 73(7), 2054-2060.
(b) Xie, X.; Tang, Y. Efficient synthesis of simvastatin by use of whole-cell biocatalysis. Appl. Environ. Microbiol., 2007, 73(7), 2054-2060.
[42]
Huang, X.; Liang, Y.; Yang, Y.; Lu, X. Single-step production of the simvastatin precursor monacolin J by engineering of an industrial strain of Aspergillus terreus. Metab. Eng., 2017, 42, 109-114.
[43]
Sanishvili, R.; Yakunin, A.F.; Laskowski, R.A.; Skarina, T.; Evdokimova, E.; Doherty-Kirby, A.; Lajoie, G.A.; Thornton, J.M.; Arrowsmith, C.H.; Savchenko, A.; Joachimiak, A.; Edwards, A.M. Integrating structure, bioinformatics, and enzymology to discover function: BioH, a new carboxylesterase from Escherichia coli. J. Biol. Chem., 2003, 278(28), 26039-26045.
[44]
Kurek, W.; Koszelewski, D.; Ostaszewski, R.; Żądło-Dobrowolska, A. Bioreactor for the continuous purification of simvastatin by lovastatin esterase. Process Biochem., 2017, 60, 92-97.
[45]
Bond, C.M.; Tang, Y. Engineering Saccharomyces cerevisiae for production of simvastatin. Metab. Eng., 2019, 51, 1-8.
Related Books
Advances in Organic Synthesis
The Synthetic Methods, Structures, and Properties of the Ca-C σ Bond Organocalcium Containing Compounds
Advances in Organic Synthesis
Chemistry of Bipyrazoles: Synthesis and Applications
Advances in Organic Synthesis
Advanced Nanocatalysis for Organic Synthesis and Electroanalysis
Advances in Organic Synthesis
Advances in Organic Synthesis
Article Metrics
37
2